Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.aat.2013.12.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of Cannabis Use Disorder in Chronic Pain: Longitudinal Links to Pain Outcomes.
J Addict Med
March 2025
Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ (CJM, IIP); Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD (CJM, CMC); College of Health Solutions, Arizona State University, Phoenix, AZ (PT); Department of Psychology, Arizona State University, Tempe, AZ (MHM); and Department of Physical Medicine and Rehabilitation, Johns Hopkins School of Medicine, Baltimore, MD (STW, RVA).
Objectives: The aim of this study was to compare individuals with chronic pain who were cannabis nonusers and those at low, moderate, and high cannabis use disorder (CUD) risk levels on baseline psychosocial and pain-related characteristics, as well as the longitudinal trajectories of pain severity and interference.
Methods: A cohort of 1453 individuals with chronic pain, recruited online, participated in this 2-year longitudinal study, which included baseline, 3-, 12-, and 24-month follow-up surveys. The Cannabis Abuse Screening Test was used to assess CUD risk, and the Brief Pain Inventory was used to assess pain outcomes.
Medical Cannabis in the United States: Comparing 2017 and 2024 State Qualifying Conditions to the 2017 National Academies of Sciences Report.
Mayo Clin Proc Innov Qual Outcomes
April 2025
Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA.
Objective: To compare the 2017 National Academies of Sciences, Engineering, and Medicine cannabis report to state medical cannabis (MC) laws defining approved qualifying conditions (QC) from 2017 and 2024 and to determine the evidence level of the QCs approved in each state.
Patients And Methods: The 2017 National Academies of Sciences (NAS) report assessed therapeutic evidence for over 20 medical conditions treated with MC. We identified the QCs of 38 states (including Washington DC) where MC was legal in 2024 and compared them to the QCs listed by these states in 2017.
Predicting therapy dropout in chronic pain management: a machine learning approach to cannabis treatment.
Front Artif Intell
February 2025
ONE-HEALTH Lab, Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Introduction: Chronic pain affects approximately 30% of the global population, posing a significant public health challenge. Despite their widespread use, traditional pharmacological treatments, such as opioids and NSAIDs, often fail to deliver adequate, long-term relief while exposing patients to risks of addiction and adverse side effects. Given these limitations, medical cannabis has emerged as a promising therapeutic alternative with both analgesic and anti-inflammatory properties.
View Article and Find Full Text PDFInternational perspectives on physician knowledge, attitudes, and practices related to medical cannabis.
Front Public Health
March 2025
Department of Psychiatry, Yale School of Medicine, New Haven, CT, United States.
Background: The trends of recreational use of cannabis and the use of cannabis for medical indications (i.e., "medical cannabis") have grown in recent years.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!